United States Oral Solid Dosage Contract Manufacturing Market Demand, Size and Competitive Analysis | TechSci Research

United States Oral Solid Dosage Contract Manufacturing Market was valued at USD 8.46 Billion in 2023 and is expected to reach USD 11.70 Billion by 2029 with a CAGR of 5.72% during the forecast period. <table><tr><td>Pages</td><td>81</td></tr> <tr><td>Market Size</td><td>2023: USD 8.46 billion</td></tr> <tr><td>Forecast Market Size</td><td>2029: USD 11.70 billion</td></tr> <tr><td>CAGR</td><td>2024-2029: 5.72%</td></tr> <tr><td>Fastest Growing Segment</td><td>Capsules</td></tr> <tr><td>Largest Market</td><td>Midwest</td></tr> <tr><td>Key Players</td><td>1.Catalent, Inc.2.Lonza Group3.AbbVie Inc.4.Aenova Group5.Adare Pharma Solutions6.Boehringer Ingelheim International GmbH7.Jubilant Pharmova Limited8.Patheon Pharma Services9.Recipharm AB10.Corden Pharma International</td></tr> </table>

美国口服固体剂型合同制造市场规模于2023年达到846亿美元，预计在预测期内将以5.72%的复合年增长率增长，并于2029年增至1170亿美元。

表格：

<table><tr><td>页数</td><td>81</td></tr> <tr><td>市场规模</td><td>2023年：846亿美元</td></tr> <tr><td>预测市场规模</td><td>2029年：1170亿美元</td></tr> <tr><td>复合年增长率</td><td>2024-2029年：5.72%</td></tr> <tr><td>增长最快的细分市场</td><td>胶囊</td></tr> <tr><td>最大市场</td><td>中西部地区</td></tr> <tr><td>主要参与者</td><td>1.Catalent, Inc.2.Lonza Group3.AbbVie Inc.4.Aenova Group5.Adare Pharma Solutions6.Boehringer Ingelheim International GmbH7.Jubilant Pharmova Limited8.Patheon Pharma Services9.Recipharm AB10.Corden Pharma International</td></tr></table>